Cryoport Inc.

Cryoport, Inc ($CYRX) today announced the launch of the MVE Biological Solutions?High-Efficiency 800 C, the latest addition to its next-gen HE Series of cryogenic freezers. Balancing high-capacity preservation with a practical and space-efficient design, the HE 800 C optimizes sample safety, retrieval, and organization. Read the full press release:? https://lnkd.in/gKhhSVUH

Cryoport, Inc. ($CYRX) today announced financial results for the fourth quarter and full year ended December 31, 2024. With considerable revenue growth from the support of commercial Cell & Gene Therapies and continued expansion in the Life Sciences Services business, we are looking forward to 2025 and are prepared to continue to grow our leading market position and open additional revenue streams that have been under development through new services and product introductions. The full financial results are available on our website at cryoportinc.com.?

Today, Cryoport, Inc. ($CYRX) will release its fourth quarter and full year 2024 financial results after market close. Following the release, our leadership team will host a Q&A conference call at 5:00 p.m. ET. A Q4 and Full Year 2024 Review document will be available in advance by 4:15 p.m. ET. For full details, please visit our website: https://cryoportinc.com.

Cryoport, Inc. ($CYRX) will announce its fourth quarter and full year 2024 financial results tomorrow, March 4, after U.S. markets close. Following the release, we invite the investment community to join a Q&A conference call at 5:00 p.m. ET, where the management team will discuss financial performance and provide business updates. For details, please visit https://lnkd.in/g_5DtNKR

Cryoport, Inc. ($CYRX) will announce its fourth quarter & full year 2024 financial results on Tuesday, March 4, after U.S. markets close. Following the release, we invite the investment community to join a Q&A conference call at 5:00 p.m. ET, where the management team will discuss financial performance and provide business updates. For details, please visit https://lnkd.in/g_5DtNKR

We are incredibly proud to share that Cryoport Systems, a Cryoport ($CYRX) subsidiary, has been honored with the Simon Ellison Supply Chain Innovation Award at the #ATW25 Conference by Phacilitate. This prestigious recognition highlights Cryoport Systems' leadership in advancing temperature-controlled supply chain solutions for the cell and gene therapy industry, ensuring that life-saving therapies reach patients with integrity and reliability.

Cryoport $CYRX subsidiary, Cryoport Systems, introduces the Cryoport Express? Cryogenic HV3 Shipping System, a state-of-the-art solution tailored to meet the unique requirements of advanced therapies and the patients they serve. ? “With the introduction of the HV3 Shipping System, we are improving patient access to vital cell therapies in smaller cities and remote areas, which will ultimately improve patient outcomes at large," said Jerrell Shelton, CEO, Cryoport. ? The HV3 system offers enhanced payload protection and ensures adherence to airline regulations by eliminating the need for palletization. Along with its integrated condition and location monitoring system, the HV3 provides full Chain of Compliance?. ? Read the full press release. https://lnkd.in/gaacixaA

Earlier this week, Cryoport ($CYRX) announced a strategic collaboration with the Moffitt Cancer Center. During the 43rd Annual J.P. Morgan Healthcare Conference, leaders from both organizations came together to celebrate this milestone and discuss potential future collaborations. Read the full press release here:?https://lnkd.in/gEpf8Vjk

Today, Jerry Shelton, President and CEO of Cryoport, Inc., delivered a presentation at the 43rd Annual J.P. Morgan Healthcare Conference. He highlighted Cryoport's fully integrated supply chain platform that enables the future of medicine for the life sciences. $CYRX Interested in learning more? You can review his presentation deck here: https://lnkd.in/gCDdsBYZ

Cryoport Inc. $CYRX is proud to announce a strategic partnership with Moffitt Cancer Center. CRYOGENE, a subsidiary?of Cryoport, Inc., will provide state-of-the-art biorepository services to Speros FL, a subsidiary of Moffitt Cancer Center. ? The CRYOGENE biostorage facility will establish Moffitt’s Speros campus as a global hub for patient treatment and research in cell and gene therapies, along with other emerging technologies and treatment pathways. ? Read The Press Release https://lnkd.in/gEpf8Vjk